Client Testimonials
We partner with clients ranging from virtual biotech companies to global pharmaceutical organisations across Europe and the USA. Here’s what they say about us.
“I think the science is very strong across multiple teams, offering significant and expert scientific input in the experimental design, execution and interpretation of results. In addition, we are running 2 IND-enabling campaigns which presents operational challenges for a small virtual biotech like ours.
Our RxC project manager has been an invaluable asset to the team, always on top of timelines, tracking budgets and managing all sample inventory and data storage. He has gone above and beyond on a number of occasions to ensure we meet out timelines.”
Orla Cunningham, Chief Scientific Officer, Granular Therapeutics, a subsidiary of Alys Pharmaceuticals
“The onboarding experience was remarkably fast and seamless. From day one, the team demonstrated an in-depth understanding of our objectives, streamlining the entire process to get us operational without delay. As such, the quick setup allowed us to start generating critical data almost immediately, enabling us to deliver key objectives faster.”
Aurore Saudemont, VP, Head of Biology, Xap Therapeutics Ltd
“From scientific execution, interpretation of the data and troubleshooting where needed, all the way through to the communication that has occurred between both organisations, I have been very impressed.
It is very clear to see the care and effort that is put in by the team at RxCelerate, and I very much look forward to working with you more in the future.”
Will Bernard, Senior Director, Cell Type Development, bit.bio
“Our successful collaboration with RxCelerate has enabled the characterisation of a number of small molecules against a novel candidate target in CAD. Once further targets are identified and validated through our BIOPATTERN trial, we hope to continue collaborating with RxCelerate to identify additional small molecule candidates whilst validating and providing new critical insights into the pathobiology of CAD”
Dr Dianne Proudfoot, Chief Scientific Officer, PlaqueTec
“I first started working with Jill and RxC in early 2013 after we founded XO1. Our previous experience with a large well-known CRO was not good; they simply followed a protocol, reported the useless ‘results’ and pocketed the money.
RxC was different. They approached each experiment as a scientific collaboration with us, eventually producing robust bleeding and thrombosis data that demonstrated a massive therapeutic index, resulting in a sale of the company to J&J after less than 2 years.
They were also pivotal in the development of SerpinPC for the treatment of haemophilia, which is now in registrational trials, and in the entire Z Factor program, which we also took to the clinic.
RxC has grown in size and capabilities over the years, absorbing or creating capabilities ranging from in silico docking, synthetic chemistry, antibody discovery and fly work, all of which my companies have benefited from. I continue to employ RxC as my go-to service provider for most of my drug discovery and development efforts.”
Professor Jim Huntington, University of Cambridge
RxCelerate offers a unique business model catering to both small molecules and biologics. We work with you to drive your asset through drug discovery, preclinical research and beyond.
Our combination of integrated teams and unique technologies allows RxCelerate to develop the optimal drug discovery strategy to deliver pharma-grade drug candidates quickly and at a fraction of the cost of traditional approaches.